Effects Zulresso on Postpartum Psychosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2024

Conditions
Postpartum Psychosis
Interventions
DRUG

Brexanolone

Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.

Trial Locations (1)

27514

UNC Hospitals, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sage Therapeutics

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT05314153 - Effects Zulresso on Postpartum Psychosis | Biotech Hunter | Biotech Hunter